These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 16947531

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature.
    Lane T, Gillmore JD, Wechalekar AD, Hawkins PN, Lachmann HJ.
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S46-53. PubMed ID: 26120866
    [Abstract] [Full Text] [Related]

  • 3. Excellent therapeutic effect of tocilizumab on intestinal amyloid a deposition secondary to active rheumatoid arthritis.
    Inoue D, Arima H, Kawanami C, Takiuchi Y, Nagano S, Kimura T, Shimoji S, Mori M, Tabata S, Yanagita S, Matsushita A, Nagai K, Imai Y, Takahashi T.
    Clin Rheumatol; 2010 Oct; 29(10):1195-7. PubMed ID: 20229259
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Clinical improvement of renal amyloidosis in a patient with systemic-onset juvenile idiopathic arthritis who received tocilizumab treatment: a case report and literature review.
    Chantarogh S, Vilaiyuk S, Tim-Aroon T, Worawichawong S.
    BMC Nephrol; 2017 May 12; 18(1):159. PubMed ID: 28499374
    [Abstract] [Full Text] [Related]

  • 8. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
    Yamada Y, Ueno T, Irifuku T, Nakashima A, Doi S, Ichinohe T, Masaki T.
    Clin Nephrol; 2018 Sep 12; 90(3):232-236. PubMed ID: 29701172
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab.
    Kuroda T, Otaki Y, Sato H, Fujimura T, Nakatsue T, Murakami S, Sakatsume M, Nakano M, Gejyo F.
    Rheumatol Int; 2008 Sep 12; 28(11):1155-9. PubMed ID: 18496698
    [Abstract] [Full Text] [Related]

  • 11. Study on the safety and efficacy of tocilizumab, an anti-IL-6 receptor antibody, in patients with rheumatoid arthritis complicated with AA amyloidosis.
    Miyagawa I, Nakayamada S, Saito K, Hanami K, Nawata M, Sawamukai N, Nakano K, Yamaoka K, Tanaka Y.
    Mod Rheumatol; 2014 May 12; 24(3):405-9. PubMed ID: 24252016
    [Abstract] [Full Text] [Related]

  • 12. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis.
    Magro-Checa C, Navas-Parejo Casado A, Borrego-García E, Raya-Álvarez E, Rosales-Alexander JL, Salvatierra J, Caballero-Morales T, Gómez-Morales M.
    Amyloid; 2011 Dec 12; 18(4):235-9. PubMed ID: 21992511
    [Abstract] [Full Text] [Related]

  • 13. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis.
    Sato H, Sakai T, Sugaya T, Otaki Y, Aoki K, Ishii K, Horizono H, Otani H, Abe A, Yamada N, Ishikawa H, Nakazono K, Murasawa A, Gejyo F.
    Clin Rheumatol; 2009 Sep 12; 28(9):1113-6. PubMed ID: 19437089
    [Abstract] [Full Text] [Related]

  • 14. Tocilizumab improves cardiac disease in a hemodialysis patient with AA amyloidosis secondary to rheumatoid arthritis.
    Hattori Y, Ubara Y, Sumida K, Hiramatsu R, Hasegawa E, Yamanouchi M, Hayami N, Suwabe T, Hoshino J, Sawa N, Oohashi K, Takaichi K.
    Amyloid; 2012 Mar 12; 19(1):37-40. PubMed ID: 22260742
    [Abstract] [Full Text] [Related]

  • 15. Long-term follow-up on tocilizumab treatment of AA amyloidosis secondary to polyarteritis nodosa.
    Ostrovršnik J, Hočevar A, Lestan B, Sodin Šemrl S, Lakota K, Tomšič M.
    Amyloid; 2016 Dec 12; 23(4):260-261. PubMed ID: 27791393
    [No Abstract] [Full Text] [Related]

  • 16. Successful use of tocilizumab in amyloidosis secondary to systemic juvenile idiopathic arthritis.
    Gupta A, Bagri NK, Tripathy SK, Barwad A, Phulware RH, Hari P.
    Rheumatol Int; 2020 Jan 12; 40(1):153-159. PubMed ID: 31273457
    [Abstract] [Full Text] [Related]

  • 17. [A case of gastrointestinal amyloidosis and hypoproteinemia improved by tocilizumab].
    Dainaka K, Isozaki Y, Kunieda K, Takayama S, Mukai R, Yamada N, Morimoto Y, Nagao Y, Oyamada H, Kawabata K.
    Nihon Shokakibyo Gakkai Zasshi; 2016 Jan 12; 113(2):245-53. PubMed ID: 26853984
    [Abstract] [Full Text] [Related]

  • 18. AA amyloidosis in a polyarteritis nodosa patient treated with tocilizumab.
    Hočevar A, Lestan B, Šemrl SS, Lakota K, Kojc N, Potočnik N, Tomšič M.
    Amyloid; 2013 Dec 12; 20(4):275-6. PubMed ID: 24106820
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.
    Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, Iwata N, Umebayashi H, Murata T, Miyoshi M, Tomiita M, Nishimoto N, Kishimoto T.
    Lancet; 2008 Mar 22; 371(9617):998-1006. PubMed ID: 18358927
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.